New PET tracer aims to spotlight immune cells in lung cancer

NCT ID NCT05933239

Recruiting now Diagnosis Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing a new radioactive imaging agent called 68GaNOTA-Anti-MMR VHH2. It is designed to attach to certain immune cells (macrophages) in non-small cell lung cancer tumors and make them visible on a PET scan. The study will involve 20 patients who are already scheduled for surgery to remove their tumor. Before surgery, they will receive an injection of the imaging agent and have a PET/CT scan. After surgery, the removed tumor tissue will be analyzed to see if the scan correctly identified the immune cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68GaNOTA-Anti-MMR-VHH2 (a radioactive imaging agent)
What this could lead to: If successful, this could lead to a better way to see certain immune cells in lung cancer tumors, helping doctors understand the tumor environment and potentially guide treatment decisions.
What could go wrong: This is a small, early-phase imaging study with only 20 participants. It is not designed to treat cancer, and the imaging agent may not reliably show the target cells in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Universitair Ziekenhuis Brussel
RECRUITING

Jette, Brussels Capital, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.